Minimally invasive coronary surgery for heart bypass
Prospective Cohort Study on Mid-term Safety and Effectiveness of Minimal Invasive Coronary Artery Bypass Grafting
This study is testing if a less invasive heart bypass surgery can help patients recover faster and feel better compared to traditional methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 25 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT04267835 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the safety and effectiveness of minimally invasive coronary artery bypass grafting (MIDCAB) procedures. It aims to assess outcomes for patients undergoing off-pump coronary artery bypass surgery through a small incision in the chest, which may reduce recovery time and trauma compared to traditional methods. The study will involve careful surgical preparation and the use of advanced techniques to perform the bypass without cardiopulmonary support. By evaluating a larger cohort than previous studies, this research seeks to establish standardized procedures and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for off-pump coronary artery bypass surgery who meet specific health criteria.
Not a fit: Patients with a BMI over 28, severe heart or respiratory conditions, or those requiring emergency surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to less invasive heart surgery with shorter recovery times for patients.
How similar studies have performed: While there have been smaller studies on MIDCAB, this research aims to provide larger-scale data, making it a novel approach in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients are planned for undergoing off-pump coronary artery bypass surgery. Exclusion Criteria: 1. BMI greater than 28 2. trauma, surgical or radiotherapy history of left chest 3. EF less than 40% 4. Simultaneous other cardiac surgery or planned cardiopulmonary bypass 5. Preoperative critical situation: acute myocardial infarction, heart failure and other conditions require emergency surgery. Preoperative nitrate drugs are difficult to control angina and needs IABP implantation. 6. Respiratory function: severe hypoxemia (pO2 less than 60 mmHg without Oxygen inhalation), carbon dioxide retention (pCO2 \> 50 mmHg), severe chronic obstructive pulmonary disease (FEV1/forced vital capacity less than 70% and FEV1 less than 50%) 7. Aortic lesions: patients with ascending aorta calcification confirmed by preoperative CT 8. Peripheral vascular lesions:By the preoperative assessment with ultrasound or CT，LIMA and left subclavian artery stenosis\>70% ,or bilateral femoral artery calcification, stenosis\>50% 9. Drug therapy: Preoperative antiplatelet or anticoagulant therapy (except aspirin and clopidogrel) 10. Others: Exclusion criteria and contraindications of CABG
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Yichen Gong, Doctor — Peking University Third Hospital
- Study coordinator: Yichen Gong, Doctor
- Email: 18611693463@126.com
- Phone: 8618611693463
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.